Global Fragment-Based Drug Discovery (FBDD) Market Analysis: Services, End Users, Growth Trends and Forecast to 2020

The global fragment-based drug discovery market is estimated to reach USD 650 Million in 2020, growing at a CAGR of 10.6% from 2016 to 2020. Increasing adoption of fragment-based screening programs by most of the major pharmaceutical companies, increasing availability of more assay options in research departments of most pharmaceutical and biotechnology companies for high hit rates of fragment-based screens are the major drivers of the global fragment-based drug discovery market, and are likely continue this trend during the forecast period.

Browse Fragment-Based Drug Discovery Market by Service Type or Components (Comparative Analysis of FBDD and HTS, Fragment Screening, Biophysical Techniques, NMR Spectroscopy, DSF Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, SPR, Bilayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, Biochemical Assays, Non-Biophysical Techniques, Fragment Optimization), and End Users (Academic and Research Institutes, Biopharmaceutical Companies, and CROs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/

Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD) is a method used for finding lead compounds as part of the drug discovery process. It is based on identifying small chemical fragments, which may bind only weakly to the biological target, and then growing them or combining them to produce a lead with a higher affinity.

The global fragment-based drug discovery market segmentation is based on service types or components (comparative analysis of FBDD and HTS, fragment screening, biophysical techniques, NMR spectroscopy, DSF assay, fluorescence polarization, isothermal titration calorimetry, X-ray crystallography, SPR, bilayer interferometry, mass spectrometry, capillary electrophoresis, biochemical assays, non-biophysical techniques, fragment optimization), and end users (academic and research institutes, biopharmaceutical companies, and CROs).

The global fragment-based drug discovery market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global fragment-based drug discovery market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global fragment-based drug discovery market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global fragment-based drug discovery market and included in this report are Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Evotec A.G., Kinetic Discovery, Proteros Fragments, Structure Based Design, Sygnature Discovery, and Sprint Bioscience AB.

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 500-7508
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.